Salmon Collagen Blood Pressure: What Residents Need

Thailand Chiang Mai University researchers have confirmed that hydrolyzed collagen extracted from salmon skin can reduce blood pressure in hypertensive subjects—a finding that could reshape how natural supplements are evaluated for cardiovascular management across Southeast Asia and beyond.

Why This Matters

• Effective dose: The study demonstrated a 450 mg/kg dose reduced systolic blood pressure comparably to enalapril, a prescription antihypertensive drug.

• Mechanism confirmed: Salmon collagen appears to work by increasing nitric oxide production, reducing inflammation, and improving blood vessel elasticity.

• Animal study only: These results come from rat models, not human trials—clinical application in Thailand remains unproven.

• Availability: Hydrolyzed collagen supplements are already sold widely in Thailand pharmacies and health stores, though dosing standards vary.

The Research Behind the Claim

A collaborative team from Chiang Mai University and Thammasat University published their findings on March 19, examining whether salmon skin-derived hydrolyzed collagen (HC) could reverse hypertension in laboratory rats. The animals were administered L-NAME, a chemical that induces high blood pressure by blocking nitric oxide production, for eight weeks. During the final four weeks, researchers introduced HC at two dosages—50 mg/kg and 450 mg/kg—alongside enalapril (10 mg/kg) as a control.

The higher collagen dose achieved a significant reduction in systolic blood pressure, matching the pharmaceutical comparator. Blood work revealed decreased oxidative stress markers and inflammatory cytokines, while serum nitric oxide levels rose. Histopathological analysis of aortic tissue showed reduced fibrosis in the tunica media and adventitia layers, suggesting that vascular remodeling was partially reversed. Acetylcholine-induced relaxation responses—a proxy for endothelial function—improved markedly in both the HC and enalapril groups.

Importantly, blood pressure in treated rats remained higher than in healthy controls, indicating that collagen supplementation alone did not fully normalize hypertension. This suggests a potential role as an adjunct therapy rather than a standalone treatment.

How Salmon Collagen Influences Blood Vessels

Hydrolyzed collagen contains bioactive peptides that inhibit angiotensin-converting enzyme (ACE), the same target of many prescription blood pressure drugs. By blocking ACE, these peptides prevent the formation of angiotensin II, a hormone that constricts blood vessels and raises blood pressure.

A second pathway involves nitric oxide, a molecule that signals blood vessels to relax. The Thailand study found that salmon collagen increased circulating nitric oxide, which improves vascular compliance and reduces arterial stiffness. This is particularly relevant in Thailand's aging population, where arterial rigidity contributes significantly to cardiovascular disease burden.

Collagen also supplies glycine and proline, amino acids that support structural integrity in vessel walls. Chronic inflammation and oxidative stress—both elevated in hypertension—degrade collagen matrices over time. Supplementation may counteract this breakdown, though the extent to which oral intake translates to vascular tissue repair remains contested in human physiology.

What This Means for Residents

For people living in Thailand managing hypertension, this research offers both promise and caution. Hydrolyzed collagen supplements are inexpensive and widely available, from Bangkok pharmacies to Chiang Mai wellness shops, often priced between ฿600 and ฿1,800 per month depending on brand and concentration.

However, the absence of human clinical trials specific to salmon collagen and blood pressure means dosing guidelines remain speculative. The rat study used 450 mg per kilogram of body weight—extrapolating to a 70 kg adult would suggest roughly 31,500 mg daily, far exceeding typical commercial doses of 2,000–5,000 mg. Meta-analyses of general collagen peptides in humans have used 900 mg to 15,000 mg per day over six to twelve weeks, yielding an average systolic blood pressure drop of 5.04 mmHg—modest but clinically meaningful for borderline hypertension.

Anyone currently prescribed ACE inhibitors, beta-blockers, or diuretics should consult a physician before adding collagen. High-protein supplementation can interfere with warfarin (a common anticoagulant in Thailand's stroke prevention protocols) and may alter the metabolism of propranolol, a beta-blocker used for hypertension and anxiety.

Comparing Natural and Pharmaceutical Options

Salmon collagen's performance in the Thailand study was notable, but established natural interventions have more robust human evidence. Garlic extract reduces systolic pressure by an average of 8.3 mmHg in hypertensive adults, slightly outperforming the collagen peptide meta-analysis average. Omega-3 fatty acids from fish oil lower systolic pressure by 1.5 mmHg in general populations, but by 4.5 mmHg in untreated hypertensive patients—comparable to moderate-dose pharmaceutical therapy.

Pharmaceutical drugs remain the gold standard. ACE inhibitors and thiazide diuretics reduce systolic pressure by 8–10 mmHg, and angiotensin II receptor blockers (ARBs) offer similar efficacy with fewer side effects. Thailand's Universal Coverage Scheme subsidizes these medications, making them affordable even in rural provinces. Collagen supplements, while accessible, are not covered by public health insurance and lack the decades of cardiovascular outcome data supporting prescription drugs.

The study's use of enalapril as a comparator is instructive: both enalapril and high-dose collagen reduced blood pressure, but neither fully normalized it. This underscores that hypertension is a multifactorial disease requiring comprehensive management—diet, exercise, weight control, and often pharmacotherapy.

Practical Considerations for Supplementation

Most collagen supplements sold in Thailand markets derive from bovine, porcine, or marine sources. Salmon collagen, specifically, is marketed as Type I collagen, which predominates in skin, bones, and vascular tissue. Marine collagen is often preferred by consumers avoiding mammalian products for religious or health reasons, aligning with Muslim dietary preferences in Thailand's southern provinces.

Reported side effects are generally mild: digestive discomfort, feelings of fullness, or heartburn. Allergic reactions occur rarely but are documented, particularly in individuals sensitive to fish proteins. Quality control varies across brands; some supplements contain added bioactive compounds that may interact unpredictably with medications.

Dosing remains inconsistent. A typical Thailand retail product provides 2,000–5,000 mg per serving, far below the rat-equivalent dose in the Chiang Mai study. Whether lower doses confer proportional benefits or require longer treatment durations is unknown. The meta-analysis of collagen peptides suggests that 12 weeks of supplementation at doses above 5,000 mg daily may be necessary for measurable blood pressure effects.

The Path Forward

The Thailand Ministry of Public Health has not issued guidance on collagen supplementation for hypertension, and the Thailand Food and Drug Administration classifies collagen as a dietary supplement rather than a therapeutic agent. This regulatory status means products are not required to demonstrate clinical efficacy, only safety.

For now, collagen supplementation may serve as a complementary strategy for individuals with prehypertension (systolic 120–139 mmHg) or as part of a broader lifestyle intervention. It should not replace prescribed antihypertensive medication without medical supervision. The Chiang Mai University findings warrant larger human trials, ideally placebo-controlled and conducted across diverse populations, to determine optimal dosing, duration, and patient subgroups most likely to benefit.

Thailand's research infrastructure—particularly at Chiang Mai and Thammasat universities—has contributed meaningfully to cardiovascular science. Translating these animal model insights into actionable clinical protocols will require collaboration between academia, Thailand's National Research Council, and the pharmaceutical industry. Until then, salmon collagen remains an intriguing but unproven adjunct in the fight against hypertension.